יחס שווי פעילות לרווח לפני ריבית, מסים ופחת Chemomab (CMMB)

Chemomab Therapeutics (CMMB) develops monoclonal antibodies to treat fibrous inflammation, ensuring high profitability through extended patent lifespans. This price chart, which serves as confirmation of the market valuation, is based on the monetization of unique formulas where a lack of analogues guarantees a stable income of 0.00. The business's resilience to external crises relies on the demand for innovation and the success of clinical trials.

For the science-driven Chemomab Therapeutics (CMMB), which invests in biologists and RSU, fluctuations in the EV/EBITDA multiple reflect the balance between the enterprise value and its operational efficiency. This indicator compares total market capitalization with pre-tax profit, allowing investors to assess the real value of assets stripped of tax distortions and to promptly identify speculative overheating of quotes.